These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 29438649)

  • 21. Epilepsy and cannabidiol: a guide to treatment.
    Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
    Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations.
    Espinosa-Jovel C
    Neurologia (Engl Ed); 2023; 38(1):47-53. PubMed ID: 34824031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?
    Cross JH; Cock H
    Neuropharmacology; 2020 Jun; 170():107861. PubMed ID: 31770546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabidiol as potential treatment in refractory pediatric epilepsy.
    Paolino MC; Ferretti A; Papetti L; Villa MP; Parisi P
    Expert Rev Neurother; 2016; 16(1):17-21. PubMed ID: 26567560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabidiol for epilepsy: trying to see through the haze.
    Detyniecki K; Hirsch LJ
    Lancet Neurol; 2016 Mar; 15(3):235-7. PubMed ID: 26776916
    [No Abstract]   [Full Text] [Related]  

  • 27. Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
    Dale T; Downs J; Olson H; Bergin AM; Smith S; Leonard H
    Epilepsy Res; 2019 Mar; 151():31-39. PubMed ID: 30771550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabinoids for epilepsy: What do we know and where do we go?
    Brodie MJ; Ben-Menachem E
    Epilepsia; 2018 Feb; 59(2):291-296. PubMed ID: 29214639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
    Nabbout R; Thiele EA
    Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
    Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
    BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
    Porter BE; Jacobson C
    Epilepsy Behav; 2013 Dec; 29(3):574-7. PubMed ID: 24237632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of cannabidiol as a treatment for severe childhood epilepsies.
    Williams CM; Stephens GJ
    Br J Pharmacol; 2020 Dec; 177(24):5509-5517. PubMed ID: 32986848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effects of cannabinoids on development/behaviour.
    Lagae L
    Epileptic Disord; 2020 Jan; 22(S1):33-37. PubMed ID: 31908315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
    Anderson LL; Heblinski M; Absalom NL; Hawkins NA; Bowen MT; Benson MJ; Zhang F; Bahceci D; Doohan PT; Chebib M; McGregor IS; Kearney JA; Arnold JC
    Br J Pharmacol; 2021 Dec; 178(24):4826-4841. PubMed ID: 34384142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The proposed mechanisms of action of CBD in epilepsy.
    Gray RA; Whalley BJ
    Epileptic Disord; 2020 Jan; 22(S1):10-15. PubMed ID: 32053110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology and drug interactions of cannabinoids.
    Landmark CJ; Brandl U
    Epileptic Disord; 2020 Jan; 22(S1):16-22. PubMed ID: 31941642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of cannabinoids in children with epilepsy: A systematic review.
    da Silva Rodrigues D; Santos Bastos Soares A; Dizioli Franco Bueno C
    Epilepsy Behav; 2023 Aug; 145():109330. PubMed ID: 37390729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
    Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
    N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of cannabinoids in the treatment of epilepsy.
    Gaston TE; Friedman D
    Epilepsy Behav; 2017 May; 70(Pt B):313-318. PubMed ID: 28087250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pharmacological Basis of Cannabis Therapy for Epilepsy.
    Reddy DS; Golub VM
    J Pharmacol Exp Ther; 2016 Apr; 357(1):45-55. PubMed ID: 26787773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.